TITLE

Treatment of pulmonary hypertension secondary to connective tissue diseases

AUTHOR(S)
Sanchez, Olivier; Humbert, Marc; Sitbon, Olivier; Simonneau, Gérald
PUB. DATE
March 1999
SOURCE
Thorax;Mar1999, p273
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66877041

 

Related Articles

  • Erratum.  // Drugs;2012, Vol. 72 Issue 12, p1708 

    A correction to the article "Treatment of Pulmonary Arterial Hypertension in Connective Tissue Disease" that was published in the May 28, 2012 issue is presented.

  • Re: Pulmonary arterial hypertension in connective tissue diseases. HLER, C. M. Kā // Rheumatology;Sep2007, Vol. 46 Issue 9, p1510 

    A letter to the editor is presented in response to a study about pulmonary arterial hypertension in connective tissue diseases.

  • Erratum.  // Rheumatology;Sep2007, Vol. 46 Issue 9, p1511 

    A correction to the article "Pulmonary Arterial Hypertension (PAH) in Connective Tissue Diseases," that was published in a 2006 issue is presented.

  • Importance of screening and early detection of pulmonary hypertension and current treatment options. Mohan, N. // Journal of Postgraduate Medicine;Apr-Jun2005, Vol. 51 Issue 2, p107 

    Points out the importance of screening and early detection of pulmonary hypertension (PHT), a common cause of death in mixed connective tissue disease (MCTD). Diagnosis of PHT; General approaches to treatment, including supplemental oxygen for hypoxemia.

  • Connective tissue associated pulmonary arterial hypertension. Coghlan, J. G.; Handler, C. // Lupus;2006, Vol. 15 Issue 3, p138 

    The number of publications in the field of pulmonary hypertension has increased exponentially over the past 10 years. As a consequence our understanding of the condition has advanced enormously. Pulmonary hypertension is now recognised as an uncommon and treatable disease, rather than a rare...

  • Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations Part I: Primary Pulmonary Hypertension. Alpert, Martin A.; Concannon, Milton D.; Mukerji, Basanti; Mukerji, Vaskar // Angiology;Aug1994, Vol. 45 Issue 8, p667 

    Efforts aimed at assessing pharmacotherapy of pulmonary arterial hypertension (PHT) have largely focused on patients with primary PHT, PHT associated with selected connective tissue diseases, and various forms of hypoxic secondary PHT. Part I of this review discusses the value and limitations of...

  • Therapy.  // Current Medical Literature: Pulmonary Hypertension;2013, Vol. 4 Issue 1, p36 

    The article presents expert commentaries on several research papers related to the treatment of pulmonary arterial hypertension. A study investigated the safety of vitamin K antagonists (VKAs) in patients with connective tissue disease-related pulmonary arterial hypertension (CTD-PAH). Another...

  • Pulmonary hypertension due to chronic hypoxia. Peacock, Andrew // BMJ: British Medical Journal (International Edition);3/24/90, Vol. 300 Issue 6727, p763 

    Examines the development of pulmonary hypertension secondary to chronic hypoxia. Concerns on the prognosis and decrease of exercise tolerance; Manifestations of the disease; Treatment of patients.

  • Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations Part II: Secondary Pulmonary Hypertension. Alpert, Martin A.; Concannon, Milton D.; Mukerji, Basanti; Mukerji, Vaskar // Angiology;Sep1994, Vol. 45 Issue 9, p755 

    Part I of this review discussed pharmacotherapy of primary pulmonary hypertension (PHT). Part II describes the value and limitations of oxygen and vasodilator therapy of secondary PHT, focusing on patients with PHT associated with selected connective tissue disease and chronic nonthrombotic...

  • Evaluation and Management of the Patient with Pulmonary Arterial Hypertension. Rubin, Lewis J.; Badesch, David B. // Annals of Internal Medicine;8/16/2005, Vol. 143 Issue 4, p282 

    Increased pressure in the pulmonary circulation, or pulmonary hypertension, is a common disorder that may complicate various cardiopulmonary conditions, including severe obstructive airways disease and left ventricular dysfunction. An increase in pulmonary arterial pressure that is not due to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics